TBCRC48 A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes "Olaparib Expanded"

Administered By

Duke Cancer Institute

Awarded By

Johns Hopkins University

Contributors

Marcom, Paul Kelly Principal Investigator

Start/End

November 26, 2018 - October 1, 2022